Merck Serono withdraws EMA application for treatment of Non Small Cell Lung Cancer - 19-Sep-2012

Merck-Serono announced the strategic decision to voluntarily withdraw the marketing authorization application to the European Medicines Agency of a label extension for Erbitux (cetuximab) in combination with standard first-line platinum-based chemotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer with high epidermal growth factor receptor expression. The decision to withdraw the application was based on feedback from European regulatory authorities, indicating that further data would be required.

Related News

Phase III study of Tomtovok (Boehringer) meets endpoint for NSCLC

IDMC halts Phase III study of Vargatef (Boehringer) in NSCLC

FDA approves Tarceva (Genentech/Astellas) for NSCLC as detected by cobas EGFR Mutation Test

NICE rejects Xalkori (Pfizer) for treatment of Non Small Cell Lung Cancer

CRLX 101 (Cerulean Pharma) fails in Phase II trial for NSCLC

NICE rejects extended use of Alimta (Eli Lilly) in NSCLC

Phase III trial of Stimuvax (Merck Serono) fails to meet primary endpoint in patients with NSCLC

New Phase II trial shows combination treatment with selumetinib (AstraZeneca) has promise for patients with NSCLC

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

22 May 2013

The Freestyle Insulinx Blood Glucose Monitoring System has been recalled by Abbott Diabetes Care in the United States. The FDA has assigned...

Read full article

Genous stent (Orbus Neich) has lower restenosis rate than bare metal stents in ACS treatment

22 May 2013

OrbusNeich announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare...

Read full article